Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox, Cholecalciferol, and Azacitidine in Elderly AML
NCT02341495Phase 2Terminated
- Start
- Feb 2013
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in acute myeloid leukemia (AML). Primary endpoint: Complete Remission Rate at 5 years. Started Feb 2013; status: terminated.
02
Drugs
deferasirox
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02341495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341495.